Ayhan Ali, Guven Suleyman, Guven Emine Seda Guvendag, Kucukali Turkan
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Acta Obstet Gynecol Scand. 2007;86(4):484-90. doi: 10.1080/00016340701226138.
To investigate whether there is a correlation between serum tumor markers panel (CA 125, CA 19-9, CA 15-3, and carcinoembryonic antigen (CEA)) and tumor size and histopathology in well staged patients with borderline ovarian tumors (BOTs).
Four tumor markers (CA 125, CA 19-9, CA 15-3, and CEA) were analysed clinically in 60 well staged patients with borderline ovarian tumor, for this retrospective observational study.
Most patients had serous histology and early stage disease, and the mean age at the time of diagnosis was 40.70 years (range: 19-73). Twenty-nine patients (48.3%) had high CA 125 levels (>35 U/l), 15 patients (25%) had high levels of CEA (>4 ng/ml), 12 patients (20%) had high levels of CA 19-9 (>37 U/ml), and 9 patients (15%) had high levels of CA 15-3 (>30 ng/ml) at the time of initial surgery. The positive rate of CA 125, CA 19-9, CA 15-3, and CEA in serous tumor were 57.9, 7.9, 7.9 and 15.8%, respectively. These figures were 31.8, 40.9, 27.3 and 40.9% in mucinous tumor. The positive rate of CA 125 in the serous group was statistically significantly higher than that in the mucinous group, while the positive rates for CA 19-9 and CEA in mucinous histology was significantly higher than those in serous tumors. In case of grouping the tumor size as <4, 4.1-10 and >10 cm, the mean serum levels of tumor markers had significantly increased by increasing tumor size (p<0.05 for CA 125, and CA 19-9, p>0.05 for CA 15-3, and CEA).
The high levels of tumor markers, especially for CA 125 and CA 19-9, may indicate the larger tumor size. The elevation of serum CA 125 may suggest serous tumors, while the high level of serum CA 19-9 and CEA may indicate mucinous BOTs.
探讨血清肿瘤标志物（CA 125、CA 19-9、CA 15-3和癌胚抗原（CEA））与分期良好的卵巢交界性肿瘤（BOTs）患者的肿瘤大小及组织病理学之间是否存在相关性。
对60例分期良好的卵巢交界性肿瘤患者进行了这一回顾性观察研究，临床分析了四种肿瘤标志物（CA 125、CA 19-9、CA 15-3和CEA）。
大多数患者为浆液性组织学类型且处于疾病早期，诊断时的平均年龄为40.70岁（范围：19-73岁）。29例患者（48.3%）CA 125水平升高（>35 U/l），15例患者（25%）CEA水平升高（>4 ng/ml），12例患者（20%）CA 19-9水平升高（>37 U/ml），9例患者（15%）初次手术时CA 15-3水平升高（>30 ng/ml）。浆液性肿瘤中CA 125、CA 19-9、CA 15-3和CEA的阳性率分别为57.9%、7.9%、7.9%和15.8%。黏液性肿瘤中的这些数字分别为31.8%、40.9%、27.3%和40.9%。浆液性组中CA 125的阳性率在统计学上显著高于黏液性组，而黏液性组织学中CA 19-9和CEA的阳性率显著高于浆液性肿瘤。将肿瘤大小分为<4 cm、4.1-10 cm和>10 cm进行分组时，肿瘤标志物的平均血清水平随肿瘤大小增加而显著升高（CA 125和CA 19-9，p<0.05；CA 15-3和CEA，p>0.05）。
肿瘤标志物水平升高，尤其是CA 125和CA 19-9，可能提示肿瘤较大。血清CA 125升高可能提示浆液性肿瘤，而血清CA 19-9和CEA水平升高可能提示黏液性BOTs。
